- /
- Supported exchanges
- / US
- / ABT.NYSE
Abbott Laboratories (ABT NYSE) stock market data APIs
Abbott Laboratories Financial Data Overview
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company provides pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Abbott Laboratories (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Abbott Laboratories data using free add-ons & libraries
Get Abbott Laboratories Fundamental Data
Abbott Laboratories Fundamental data includes:
- Net Revenue: 43 843 M
- EBITDA: 11 747 M
- Earnings Per Share: 7
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-10-15
- EPS/Forecast: 1.3
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Abbott Laboratories News
New
Top Analyst Reports for HSBC, Abbott & Shell
Thursday, December 4, 2025 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including HSBC Ho...
CureVac N.V. (CVAC): A Bull Case Theory
We came across a bullish thesis on CureVac N.V. on Ridire Research’s Substack. In this article, we will summarize the bulls’ thesis on CVAC. CureVac N.V.'s share was trading at $5.20 as of Decemb...
Muscles, the New Flex: Abbott Launches Two New Ensure® Max Protein Shakes to Tap into Growing Muscle Health Movement
Aging, nutrition and lifestyle affect muscles, especially after age 40. That's why Matt Ryan, former professional quarterback and MVP, is teaming up with Abbott to drive muscle health awareness with t...
Could Buying AbbVie Today Set You Up for Life?
Key Points AbbVie has performed exceedingly well over the past 12 years. The company still has many of the traits that led to that result. It looks likely to deliver superior returns again over the l...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.